NCT04697758View on ClinicalTrials.gov

Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 10, 2020

Primary Completion Date

October 1, 2022

Study Completion Date

October 1, 2022

Conditions
Diabetic Macular Edema (DME)
Interventions
DRUG

AXT107 0.1 mg

Single intravitreal injection of AXT107 0.1 mg/eye

DRUG

AXT107 0.25 mg

Single intravitreal injection of AXT107 0.25 mg/eye

DRUG

AXT107 0.5 mg

Single intravitreal injection of AXT107 0.5 mg/eye

Trial Locations (10)

19107

AsclepiX Investigative Site, Philadelphia

33711

AsclepiX Investigative Site, St. Petersburg

77384

AsclepiX Investigative Site, The Woodlands

78550

AsclepiX Investigative Site, McAllen

79606

AsclepiX Investigative Site, Abilene

85053

AsclepiX Investigative Site, Gilbert

89502

AsclepiX Investigative Site, Reno

90211

AsclepiX Investigative Site, Los Angeles

97401

AsclepiX Investigative Site, Eugene

02114

AsclepiX Investigative Site, Boston

Sponsors
All Listed Sponsors
lead

AsclepiX Therapeutics, Inc.

INDUSTRY

NCT04697758 - Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema | Biotech Hunter | Biotech Hunter